These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957 [TBL] [Abstract][Full Text] [Related]
5. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile? Hashmi NA; Cosgrove JF; MacMahon P Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917 [TBL] [Abstract][Full Text] [Related]
6. Palivizumab in the prevention of respiratory syncytial virus disease. Krilov LR Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675 [TBL] [Abstract][Full Text] [Related]
7. Strategies for preventing respiratory syncytial virus. Forbes M Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197 [TBL] [Abstract][Full Text] [Related]
8. [Respiratory syncytial immunoprophylaxis with palivizumab]. De Halleux V; Lombet J; Rigo J Rev Med Liege; 2007; 62(5-6):299-302. PubMed ID: 17725198 [TBL] [Abstract][Full Text] [Related]
9. Current strategies in the prevention of respiratory syncytial virus disease. Paes BA Paediatr Respir Rev; 2003 Mar; 4(1):21-7. PubMed ID: 12615029 [TBL] [Abstract][Full Text] [Related]
10. A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy. Noor A; Krilov LR J Pediatric Infect Dis Soc; 2024 Jul; 13(Supplement_2):S103-S109. PubMed ID: 38577737 [TBL] [Abstract][Full Text] [Related]
11. Prevention of respiratory syncytial virus infection with palivizumab. Thomas M; Bedford-Russell A; Sharland M Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088 [TBL] [Abstract][Full Text] [Related]
13. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
14. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Meissner HC; Long SS; Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628 [TBL] [Abstract][Full Text] [Related]
15. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627 [TBL] [Abstract][Full Text] [Related]
16. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Feltes TF; Sondheimer HM Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335 [TBL] [Abstract][Full Text] [Related]
17. Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants. Lanari M; Silvestri M; Rossi GA Curr Drug Metab; 2013 Feb; 14(2):216-25. PubMed ID: 22935064 [TBL] [Abstract][Full Text] [Related]
18. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Fitzgerald DA Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385 [TBL] [Abstract][Full Text] [Related]
19. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Resch B Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249 [TBL] [Abstract][Full Text] [Related]